Stanford’s lysosome protein degradation spinout Lycia emerged with $50m of capital from Versant Ventures to develop a portfolio of drug candidates.

Lycia Therapeutics, a US-based protein degradation drug development spinout of Stanford University, exited stealth on Tuesday with $50m from founding investor Versant Ventures. Lycia Therapeutics has built a drug discovery platform for creating lysosome targeting chimeras (Lytacs) capable of degrading cell-surface proteins ordinarily inaccessible with traditional therapeutic methods, combatting intractable diseases including certain subtypes of…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.